Stocks of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) traded higher last session on Wall Street, down -18.27% to $0.29.
According to the data, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has 1 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $1.00 and a low of $1.00, we find $1.00. Given the previous closing price of $0.36, this indicates a potential upside of 177.78 percent. GLMD stock price is now -37.77% away from the 50-day moving average and -91.01% away from the 200-day moving average. The market capitalization of the company currently stands at $1.12M.
A total of 0 analysts have issued a hold rating and 1 have given it a buy rating. Brokers who have rated the stock have averaged $1.00 as their price target over the next twelve months.
With the price target reduced from $11 to $8, B. Riley FBR Downgraded its rating from Buy to Neutral for Galmed Pharmaceuticals Ltd (NASDAQ: GLMD).
A total of 6.88% of the company’s stock is owned by insiders.
Wednesday’s opening bell rang with an opening price of $0.3168 for Galmed Pharmaceuticals Ltd (NASDAQ: GLMD). During the past 12 months, Galmed Pharmaceuticals Ltd has had a low of $0.26 and a high of $14.18. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.59, and a quick ratio of 3.59. The fifty day moving average price for GLMD is $0.4729 and a two-hundred day moving average price translates $1.2483 for the stock.
The latest earnings results from Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was released for Jun, 2023.
Galmed Pharmaceuticals Ltd(GLMD) Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
